Photodynamic therapy involves injecting a light-sensitizing drug and passing a red-light laser through the endoscope to activate the medication, destroying the abnormal Barrett's esophagus tissue.
In this therapy, a light-sensitizing drug is injected and a red-light laser is passed through the endoscope to activate the medication, leading to the abnormal Barrett's esophagus mucosa tissue being destroyed.
Photodynamic therapy has been approved for the treatment of Barrett's esophagus with high-grade dysplasia. Kenneth K. Wang, M.D., has been one of the pioneers in this field and has been performing photodynamic therapy for more than a decade.
In a current study supported by the National Cancer Institute, people with Barrett's esophagus and early esophageal cancer undergo molecular testing to determine if they will respond to photodynamic therapy.